Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Other Non-Current Assets (2023 - 2025)

Historic Other Non-Current Assets for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $7.5 million.

  • Nuvation Bio's Other Non-Current Assets rose 145458.33% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 145458.33%. This contributed to the annual value of $6.8 million for FY2024, which is 105178.88% up from last year.
  • Latest data reveals that Nuvation Bio reported Other Non-Current Assets of $7.5 million as of Q3 2025, which was up 145458.33% from $6.6 million recorded in Q2 2025.
  • Nuvation Bio's 5-year Other Non-Current Assets high stood at $7.5 million for Q3 2025, and its period low was $138000.0 during Q1 2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $1.1 million (2024), whereas its average is $2.9 million.
  • As far as peak fluctuations go, Nuvation Bio's Other Non-Current Assets crashed by 1822.83% in 2024, and later soared by 145458.33% in 2025.
  • Nuvation Bio's Other Non-Current Assets (Quarter) stood at $587000.0 in 2023, then skyrocketed by 1051.79% to $6.8 million in 2024, then increased by 10.37% to $7.5 million in 2025.
  • Its Other Non-Current Assets was $7.5 million in Q3 2025, compared to $6.6 million in Q2 2025 and $6.6 million in Q1 2025.